Trump’s ‘America First’ Trade Strategy Expands to Pharmaceuticals: A Deep Dive into Potential Impacts
WASHINGTON (AP) — In a significant expansion of his “America First” trade strategy, President Donald Trump is preparing to levy substantial import taxes on pharmaceuticals, a sector previously largely exempt from his sweeping tariff policies. This move, which could see duties soar from zero to potentially over 200%, has ignited a debate among economists, healthcare experts, and industry leaders about its potential to disrupt global supply chains, drive up drug costs for American consumers, and even trigger critical shortages.
For years, imported medicines have entered the United States largely duty-free. However, the landscape is now shifting. Recent discussions between U.S. and European leaders have outlined a new trade agreement that includes a 15% tariff on certain European pharmaceutical goods. More dramatically, President Trump has threatened tariffs of 200% or more on drugs manufactured in other parts of the world.
“Shock and awe” is how Maytee Pereira, a tax and consulting expert at PwC, characterized Trump’s plans for the pharmaceutical industry. “This is an industry that’s going from zero (tariffs) to the potentiality of 200%,” she noted, underscoring the unprecedented nature of the proposed taxes.
The Paradox of Price Reduction vs. Protectionism
President Trump has consistently vowed to lower drug costs for Americans, even recently urging pharmaceutical companies to adopt “most-favored nation” pricing. Yet, economists warn that imposing stiff tariffs on imported pharmaceuticals could have the opposite effect, directly contradicting his stated goal. Diederik Stadig, a healthcare economist with financial services firm ING, highlighted this concern, stating in a recent commentary, “A tariff would hurt consumers most of all, as they would feel the inflationary effect… directly when paying for prescriptions at the pharmacy and indirectly through higher insurance premiums.” Stadig further warned that lower-income households and the elderly would likely bear the brunt of these increased costs.
Moreover, these tariffs risk disrupting the intricate global pharmaceutical supply chains, which have become increasingly interdependent over decades. The potential for driving cheap, foreign-made generic drugs out of the U.S. market and creating shortages is a significant concern. The U.S. trade deficit in medicinal and pharmaceutical products stood at nearly $150 billion last year, reflecting the nation’s heavy reliance on overseas production.
Industry Prepares for Impact, But Challenges Remain
Recognizing the looming threat, many drugmakers have already begun taking precautionary measures. Trump has indicated a delay in the tariffs for 12 to 18 months, offering companies a window to stockpile medicine or shift manufacturing to the United States. Leerink Partners analyst David Risinger reported in a July 29 note that most drugmakers have increased drug product imports, accumulating between six and 18 months of inventory in the U.S.
Jefferies analyst David Windley suggests that even if tariffs are implemented in the latter half of 2026, their full impact might not be felt until 2027 or 2028 due to these stockpiles. Many analysts also anticipate that Trump might ultimately settle for a tariff rate significantly lower than the threatened 200% and hope for exemptions for critical, low-margin generic drugs. Nevertheless, Stadig warns that even a 25% levy could gradually increase U.S. drug prices by 10% to 14% as existing stockpiles diminish.
Major pharmaceutical companies have also announced significant investments in their U.S. operations. Swiss drugmaker Roche disclosed plans in April to invest $50 billion in expanding its U.S. footprint. Johnson & Johnson is set to spend $55 billion within the United States over the next four years, with CEO Joaquin Duato expressing the company’s ambition to supply the U.S. market entirely from domestic sites.
However, reshoring pharmaceutical manufacturing is a complex and costly endeavor, often taking several years to establish new factories. A significant hurdle lies in the origin of active pharmaceutical ingredients (APIs). Jacob Jensen, a trade policy analyst at the American Action Forum, points out that “97% of antibiotics, 92% of antivirals and 83% of the most popular generic drugs contain at least one active ingredient that is manufactured abroad.” This means that simply assembling drugs in the U.S. wouldn’t fully insulate companies from tariffs on imported ingredients. “The only way to truly protect yourself from the tariffs would be to build the supply chain end to end in the United States,” Pereira emphasized.
National Security and the Fragile Generic Market
Beyond economic concerns, national security is a driving factor behind Trump’s push. The COVID-19 pandemic starkly highlighted the vulnerabilities of relying on foreign nations for essential medicines and medical supplies, especially when key suppliers are geopolitical rivals like China. In April, the administration launched an investigation under Section 232 of the Trade Expansion Act of 1962, which allows the president to impose tariffs for national security reasons, to assess how drug and ingredient imports affect national security.
While some experts see a role for tariffs in securing U.S. medical supplies, the delicate balance is crucial. Marta Wosińska, a health policy analyst at the Brookings Institution, cited the Biden administration’s successful taxation of foreign syringes as an example where tariffs prevented cheap Chinese imports from undermining domestic producers. However, she cautions that generic drug manufacturers, operating on thin profit margins, are particularly vulnerable. A production pause at a factory in India a couple of years ago, for instance, led to a chemotherapy shortage that severely disrupted cancer care, illustrating the fragility of these markets. “If there’s a shock, it’s hard for them to recover,” Wosińska noted.
Wosińska argues that tariffs alone are unlikely to incentivize generic drug manufacturers to build U.S. factories; government financing would likely be essential. “In an ideal world, we would be making everything that’s important only in the U.S.,” she said. “But it costs a lot of money… We have offshored so much of our supply chains because we want to have inexpensive drugs. If we want to reverse this, we would really have to redesign our system… How much are we willing to spend?” The question of cost and commitment looms large as the U.S. grapples with the future of its pharmaceutical supply.
